OBJECTIVES Pharmacoeconomic analysis of rosuvastatin use in patients with hypercholesterolemia in the health care of Belarus has been performed to determine economic advisability of its applying in Belarus. As there is own production of statins (generics of lovastatin, atorvastatin and simvastatin) in Belarus, the insclusion of new statin (rosuvastatin) in the clinical protocols requires pharmacoeconomic study. METHODS Overview of statins available in Belarus has been conducted. Equivalent effective dose to achieve target of low density lipoprotein cholesterol (CH-LPLD) values were established on the basis of published data. Cost-minimization analysis has been used. Model "decision tree" to achieve the target CH-LPLD values has been built on the basis of STELLAR trial. Statin doses required to achieve the target CH-LPLD values have been calculated. The costs of achieving the target CH-LPLD values have been evaluated. The cost of each statins treating during the year has been calculated. RESULTS The highest cost has been obtained for the equivalent dose of lovastatin ($ 0.35) compared with atorvastatin ($ 0.31) and simvastatin ($ 0.28) manufactured in Belarus. Average price rosuvastatin (Merten ®) was comparable to the cost ($ 0.21) of Belarusian generics. The average cost of achieving the target CH-LPLD level was the lowest in the case of rosuvastatin - $ 170 compared with atorvastatin ($ 200) and simvastatin ($ 286) considering available statins of all manufacturers.Due to rosuvastatin’s lower effective dosage the costs of the one-year treatment with rosuvastatin is lower (on average 94 $) than with atorvastatin (all manufacturers - $ 100) and simvastatin (202 $).   CONCLUSIONS The study has demonstrated pharmacoeconomic acceptability of rosuvastatin use in the health care of Belarus.